...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery
【24h】

A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery

机译:由修饰的蛋白质和脂质组成的新型脂蛋白模拟纳米载体,用于靶向肿瘤细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Ursodeoxycholic acid (UA) modified protein-lipid nanocomplex (uP-LNC) as a novel biomimetic nanocarrier was developed for tumor-targeting delivery. Bovine serum albumin (BSA) was used as a model protein and its amino groups were covalently modified by UA. Lipid nanoparticle (LNP) composed of phospholipids, triglycerides and octadecylamine was prepared by using solvent evaporation method and was used as the core. UA modified BSA (uP) was attached onto the surface of LNP by post-insert method and generated the protein-lipid nanocomplex. As the control, cholesteryl hemiglutarate (CH), a non-targeting ligand was also used to modify BSA and then formed CH modified protein-lipid nanocomplex (cP-LNC). The combining efficiency of modified BSA with LNP, determined by Bradford protein assay, increased with the enhancement of substitution degree. The modified BSA and nanocomplex were characterized for the substitute degree, average molecular weight, surface tension, particle size and zeta potential by various physicochemical analyses. In vitro dissolution tests and cell uptake studies were performed by loading coumarin-6 as a fluorescent probe. The results indicated that the UA modified protein attached on the nanoparticles significantly decreased drug release from the nanocomplex in pH 7.4 medium, The uptake of uP-LNC was higher in hepatic carcinoma cells (HepG2 and Bel 7402) than in normal liver cells (L02). Furthermore, the uptake of uP-LNC was significantly higher than that of cP-LNC and LNP in these cells. The uptake was dependent on time, temperature and concentration, and could be inhibited by free UA. In addition, the MTT assay of uP-LNC and u_xP with various degrees of substitution showed very low cytotoxicity at tested concentrations in all cells. The UA modification served to facilitate the specific receptor and energy mediated endocytosis process of the protein-lipid nanocomplex and enabled this nanocomplex to be a potential nanocarrier for tumor-targeting drug delivery.
机译:熊去氧胆酸(UA)修饰的蛋白质-脂质纳米复合物(uP-LNC)作为新型仿生纳米载体被开发用于靶向肿瘤。牛血清白蛋白(BSA)被用作模型蛋白,其氨基被UA共价修饰。采用溶剂蒸发法制备了由磷脂,甘油三酸酯和十八烷基胺组成的脂质纳米颗粒(LNP),并以其为核心。 UA修饰的BSA(uP)通过插入后方法附着在LNP的表面上,并生成蛋白质-脂质纳米复合物。作为对照,非目标配体胆固醇半戊二酸酯(CH)也用于修饰BSA,然后形成CH修饰的蛋白质-脂质纳米复合物(cP-LNC)。通过Bradford蛋白分析确定的修饰BSA与LNP的结合效率随取代度的提高而增加。通过各种理化分析,对改性的牛血清白蛋白和纳米复合物的取代度,平均分子量,表面张力,粒径和ζ电势进行了表征。通过加载香豆素-6作为荧光探针来进行体外溶出度测试和细胞摄取研究。结果表明,附着在纳米颗粒上的UA修饰蛋白可显着降低pH 7.4介质中纳米复合物的药物释放。肝癌细胞(HepG2和Bel 7402)中uP-LNC的摄取高于正常肝细胞(L02) 。此外,在这些细胞中,uP-LNC的摄取明显高于cP-LNC和LNP。摄取取决于时间,温度和浓度,并且可以被游离UA抑制。另外,具有不同取代度的uP-LNC和u_xP的MTT分析在所有细胞中的测试浓度下均显示出极低的细胞毒性。 UA修饰用于促进蛋白质-脂质纳米复合物的特异性受体和能量介导的内吞作用过程,并使该纳米复合物成为靶向肿瘤的药物递送的潜在纳米载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号